Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S.

SUZHOU, China, April 25, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the phase III clinical trial of proxalutamide for the treatment of male...

from PR Newswire: https://ift.tt/3vlyyj8